Bio-Path Holdings, Inc. (BPTH)
| Previous close | 2.7600 |
| Open | 2.7600 |
| Bid | 2.7300 x 100 |
| Ask | 2.8600 x 100 |
| Day's range | 2.6500 - 2.8600 |
| 52-week range | 2.3500 - 44.8000 |
| Volume | |
| Avg. volume | 1,490,227 |
| Market cap | 4.336M |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -33.6300 |
| Earnings date | 15 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 40.00 |
GlobeNewswireBio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 15, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview. To access the live conference
- GlobeNewswire
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 375,000 shares of its common stock at a purchase price of $3.225 per share and c
ZacksBio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
